Stallergenes Greer Authorized to Resume Named Patient Products Manufacturing at Its Antony, France Plant

Regulatory News:

Stallergenes Greer plc (the "Company”) (Euronext Paris:STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that it has been authorized to restart the manufacturing of its Named Patient Products (NPP) after a temporary suspension at its Stallergenes SAS plant in Antony, France. NPP products, such as STALORAL^® will be progressively available again to our patients.

This temporary suspension was enacted following observations made by the French Health Authority (ANSM), regarding the implementation of a new IT system. The launch of this IT system, aimed at providing upgraded supply and delivery of Stallergenes Greer’s products, resulted in operational disruptions that have now been fully addressed. This suspension lift enables Stallergenes Greer to fully resume its activities, according to a progressive restart plan.

"We are very pleased with the resumption of NPP production, notably STALORAL^® which has been the most prescribed sublingual allergy immunotherapy worldwide,” said Fereydoun Firouz, Chairman and Chief Executive Officer of Stallergenes Greer. "The temporary suspension was the result of issues with the IT interfaces which are now fully resolved. With a fully operational ERP system now in place, Stallergenes Greer is setting the stage for a transformative business culture. We have emerged from this technical challenge stronger as an organization, wiser and more determined than ever to realize our long-term curative ambitions for our patients.”

ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification 4577

Market: Euronext Paris regulated market

Additional information is available at http://www.stallergenesgreer.com

This document (including information incorporated by reference in this document), oral statements made and other information published by the company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in our prospectus filed with the French Autorité des marchés financiers on September 3, 2015. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160310006240/en/